Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Current Assets (2017 - 2025)

Cue Biopharma's Current Assets history spans 9 years, with the latest figure at $25.8 million for Q3 2025.

  • For Q3 2025, Current Assets fell 30.7% year-over-year to $25.8 million; the TTM value through Sep 2025 reached $25.8 million, down 30.7%, while the annual FY2024 figure was $25.1 million, 51.14% down from the prior year.
  • Current Assets for Q3 2025 was $25.8 million at Cue Biopharma, down from $30.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $79.7 million in Q2 2021 and bottomed at $15.9 million in Q1 2025.
  • The 5-year median for Current Assets is $60.9 million (2023), against an average of $54.3 million.
  • The largest annual shift saw Current Assets soared 51.21% in 2021 before it plummeted 64.34% in 2025.
  • A 5-year view of Current Assets shows it stood at $68.5 million in 2021, then grew by 12.73% to $77.2 million in 2022, then plummeted by 33.34% to $51.5 million in 2023, then plummeted by 51.14% to $25.1 million in 2024, then rose by 2.71% to $25.8 million in 2025.
  • Per Business Quant, the three most recent readings for CUE's Current Assets are $25.8 million (Q3 2025), $30.8 million (Q2 2025), and $15.9 million (Q1 2025).